Metastatic renal cell carcinoma
Conditions
Brief summary
To evaluate the tumor detectability/detection rate (descriptive) of 68Ga-gozetotide (PSMA) PET-CT compared to 89Zr-DFO-girentuximab PET-CT (both in addition to conventional contrast enhanced CT) in patients with the suspicion of metastatic ccRCC. The denominator will consist of the conventional diagnostic contrast enhanced CT, 68Ga-gozetotide (PSMA) PET-CT and 89Zr-DFO-girentuximab PET-CT.
Detailed description
The semi-quantitative assessment of the SUVmax in primary tumor (if in situ) and SUVmax of metastases (lesion based analyses)., Tumor-to-background ratio of primary tumor (if in situ) and tumor-to-background ratio of metastases.
Interventions
Sponsors
Stichting Radboud universitair medisch centrum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the tumor detectability/detection rate (descriptive) of 68Ga-gozetotide (PSMA) PET-CT compared to 89Zr-DFO-girentuximab PET-CT (both in addition to conventional contrast enhanced CT) in patients with the suspicion of metastatic ccRCC. The denominator will consist of the conventional diagnostic contrast enhanced CT, 68Ga-gozetotide (PSMA) PET-CT and 89Zr-DFO-girentuximab PET-CT. | — |
Secondary
| Measure | Time frame |
|---|---|
| The semi-quantitative assessment of the SUVmax in primary tumor (if in situ) and SUVmax of metastases (lesion based analyses)., Tumor-to-background ratio of primary tumor (if in situ) and tumor-to-background ratio of metastases. | — |
Countries
Netherlands
Outcome results
None listed